ARTICLE | Clinical News
ARQ 501: Phase I data
April 10, 2006 7:00 AM UTC
Data from a dose-escalation Phase I trial in 64 patients, who failed chemotherapy, showed that 18 of 38 evaluable patients had antitumor activity. Of those 18, evidence of tumor regression was seen in...